Esomeprazole delayed-release - Dexcel Pharma
Latest Information Update: 31 Oct 2021
At a glance
- Originator Dexcel-Pharma
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antibacterials; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Heartburn
Most Recent Events
- 23 Dec 2020 Chemical structure information added
- 05 Nov 2020 Esomeprazole delayed-release is available for licensing as of 05 Nov 2020. https://dexcel.com/
- 05 Nov 2020 Dexcel Pharma has patent protection for its proprietary oral drug delivery technologies (Dexcel Pharma website, November 2020)